ABCURO

Newton, Massachusetts, December 6, 2023- Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Mark Pruzanski, M.D., as Chairman of its Board of Directors. Dr. Pruzanski brings more than 30 years of experience as... Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.

Also known as: Abcuro, Inc.

Primary location: Newton United States